Navigation Links
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
Date:4/1/2013

egeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company plans to initiate a Phase 1 clinical trial in Sweden during the second quarter of 2013 for the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements using words such as anticipate, expect, project, intend, plan, believe, words and terms of similar substance and any discussion of future plans, actions, or events generally identify forward-looking statements. Forward-looking statements regarding the Company include but are not limited to (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney Augment; and (ii) expectations regarding ongoing and planned preclinical studies, clinical trials and related filings or submissions with regulatory authorities.  Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. Tengion's business is subject to significant risks and uncertainties and there can be no assurance that actual results will not differ materially from expectations.  Factors which could cause actual results to differ materially from expectations include, among others: (i) the U.S. Food and Drug Administration could place the Neo-Urinary Conduit clinical trial on clinical hold; (ii) the Medical Products Agency could place the Neo-Kidney Augment clinical trial on clinical ho
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Reports Second Quarter 2012 Financial Results
2. Tengion to Present at the BIO CEO & Investor Conference
3. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
4. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
5. Nephros Receives 510(k) Clearance for Hemodiafiltration System
6. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
7. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
8. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 After 6 months of careful ... here - the new programme for the next Cool Chain ... our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and ... that is broad and yet specific, focused and yet accessible, ...
(Date:9/18/2014)... Calif. , Sept. 18, 2014   ... ), a biopharmaceutical company leading the discovery and ... it has initiated its ATHENA natural history of ... life-threatening genetic kidney disease with no approved therapy. ... natural decline of renal function markers such as ...
(Date:9/18/2014)... , Sept. 18, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that the ... Geert Cauwenbergh , will present at ... Conference on Wednesday, September 24, 2014 at ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... MADISON, N.J., March 28, 2011 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today it ... subsidiary, Spark Acquisition Corporation, for all of the outstanding ... (Nasdaq: CRA ), one of the world,s ...
... (Nasdaq: VRUS ) today announced that it will ... Study of the Liver (EASL) on Saturday, April 2, 2011 ... Pharmasset,s progress on the programs that are the subject of ... a simultaneous webcast of this event via the internet, log ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 Clinical ... provides data on the Edema clinical trial scenario. This ... clinical trials on Edema. It includes an overview of ... the site of trial conduction across the globe. The ... by their phase, trial status, prominence of the sponsors ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Cary, NC (PRWEB) September 18, 2014 Relias ... the health and human services markets, today announced it has ... the fastest growing private companies in America. , In the ... growth, and moved up almost 2,000 spots on the Inc. ... in 2012. , “The industries we serve continue ...
(Date:9/18/2014)... Schaumburg, IL (PRWEB) September 18, 2014 ... proving itself a boon to contractors and homeowners ... construction dust that overtakes the home, causes potential ... project. Now available nationwide, the BuildClean system allows ... from demolition, sanding and other standard remodeling tasks. ...
(Date:9/18/2014)... Maureen Salamon HealthDay ... -- Migraines in midlife may be associated with increased ... in later years, new research suggests. The study, ... two brain-based conditions, also suggested that the migraine-Parkinson,s association ... An aura is a warning sign of a pending ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... KENILWORTH, N.J., July 24 Schering-Plough Corporation (NYSE: ... Court approval, to resolve litigation seeking to enjoin the planned ... relief. The consolidated class action lawsuits, previously reported in ... in U.S. District Court for the District of New Jersey. ...
... , , , ... ( www.medworksusa.org ) will provide free access for the uninsured ... a.m. to 4 p.m. Saturday and Sunday, July 25 and 26, at ... mass health clinic sponsored by MedWorks and will provide 1100 medical, 300 ...
... WASHINGTON, July 24 Medicine and healing have long been ... years, the debate about the nature of the relationship between ... book, "Spirituality and Medicine: Can the Two Walk Together?" ( ... Ph.D., J.D., M.Div., and Harold B. Betton, M.D., Ph.D., offer ...
... LINTHICUM, Md., July 24 Dialysis Corporation of America (Nasdaq: ... second quarter 2009 financial results on Wednesday August 5, 2009, after ... conference call in conjunction with its second quarter 2009 earnings release ... , , Those interested in ...
... Foundation Radiology Group (FRG), the premier provider of diagnostic imaging ... the addition of Jim Yamshak, Senior Vice President of Sales, ... , , Jim Yamshak, a ... to the FRG team. Most recently, Mr. Yamshak served as ...
... ARBOR, Mich., July 24 As the economy continues to falter, a ... to spend what money they have, and children -- especially those who ... more at risk because of it. , , ... in May 2009 shows 44 percent of families, financial situations have worsened ...
Cached Medicine News:Health News:Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:'Spirituality and Medicine: Can the Two Walk Together?' 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 3Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 3
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: